Systemic and Renal Pharmacokinetics of Adefovir and Tenofovir Upon Coadministration

Adefovir and tenofovir are nucleotide analogs that undergo renal secretion by the human renal organic anion transporter. The pharmacokinetics of tenofovir and adefovir following the administration of tenofovir disoproxil fumarate and adefovir dipivoxil alone and together were determined in 24 healthy subjects in an 8‐day, open‐label, fixed‐sequence study. Subjects received oral doses of adefovir dipivoxil on days 1 and 8 and oral doses of tenofovir disoproxil fumarate on days 2 to 8. Pharmacokinetic sampling was performed on days 1, 7, and 8. The plasma pharmacokinetics of tenofovir and adefovir were unaltered upon coadministration. Furthermore, the renal clearances (CLrenal) of tenofovir and adefovir were unaffected by their coadministration. The plasma Cmax values of tenofovir and adefovir were 33‐fold and 340‐fold lower than their Km values for the human renal organic anion transporter. These results demonstrate that coadministration of tenofovir disoproxil fumarate and adefovir dipivoxil does not result in substantial changes to their individual pharmacokinetic profiles.

[1]  R. Ebrahimi,et al.  Adefovir dipivoxil safety and pharmacokinetics in subjects with hepatitis B virus infection and in healthy subjects , 2002 .

[2]  A. Collier,et al.  Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients , 1995, Antimicrobial agents and chemotherapy.

[3]  T. Cihlar,et al.  Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. , 2000, The Journal of pharmacology and experimental therapeutics.

[4]  T. Cihlar,et al.  The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. , 1999, Molecular pharmacology.

[5]  J. Kahn,et al.  Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults , 2001, Antimicrobial Agents and Chemotherapy.

[6]  K. A. Mattes,et al.  Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. , 2003, Clinical therapeutics.

[7]  T. Antoniou,et al.  Tenofovir: A Nucleotide Analog for The Management of Human Immunodeficiency Virus Infection , 2003, Pharmacotherapy.

[8]  Nicholson,et al.  Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L‐FMAU, DAPD, penciclovir and lobucavir , 2000, Journal of viral hepatitis.

[9]  J. Phair,et al.  Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection. , 1990, American journal of public health.

[10]  T. Cihlar,et al.  Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. , 2000, Journal of the American Society of Nephrology : JASN.

[11]  T. Cihlar,et al.  NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 20(4–7), 641–648 (2001) HUMAN RENAL ORGANIC ANION TRANSPORTER 1 (hOAT1) AND ITS ROLE IN THE NEPHROTOXICITY OF ANTIVIRAL NUCLEOTIDE ANALOGS , 2003 .

[12]  V. Calvez,et al.  Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study , 2001, The Lancet.

[13]  V. Calvez,et al.  Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine , 2002, Antimicrobial Agents and Chemotherapy.

[14]  B. Gazzard,et al.  An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals , 2003, AIDS.

[15]  B. Kearney,et al.  A drug-drug interaction study between adefovir dipivoxil and lamivudine, acetaminophen, ibuprofen and trimethoprim/sulfamethoxazole , 2002 .

[16]  R. Bruno,et al.  Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. , 2002, AIDS reviews.

[17]  E. De Clercq,et al.  Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine , 1993, Antimicrobial Agents and Chemotherapy.